1. Products > NCI-H358 Transfection Reagent (Bronchioalveolar Cells)
Altogen labs
Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products
Products > NCI-H358 Transfection Reagent (Bronchioalveolar Cells)
Altogen Biosystems offers the NCI-H358 Cell Transfection Reagent among a host of 100+ cell line specific In Vitro Transfection Kits.
The NCI-H358 Cell Transfection Reagent is a nanoparticle-based liposome formulation, and it has been developed to provide high transfection efficiency with NCI-H358.
This cell line is a good host for studying lung cancer as well as a range of areas within the field of biomedical therapeutics and biology. When cultured in vitro, NCI-H358 cells are a monolayer and adhere to the surface of the culture flask.
Other applications include drug discovery, gene expression studies, molecular and cell biology research applications.
Purchase NCI-H358 Transfection Kit at
Altogen Biosystems  848 Rainbow Blvd #823  Las Vegas  NV   USA
Telephone   Fax   

2. High Density NCI-H358 cells
Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products
Products > NCI-H358 Transfection Reagent (Bronchioalveolar Cells)
NCI-H358 Cell Line Description and Applications
The NCI-H358 cell line was established by A.F. Gazdar, H.K. Oie, J.D. Minna and associated scientists in The cell line was derived from tumorigenic lung tissue, and bronchiole or alveolus tissue specifically. The male patient suffered from bronchioalveolar carcinoma, and the tissue was removed before the initiation of chemotherapy. The NCI-H358 cell line expresses the RNA of SP-A, the protein associated with lung surfactant. The cell line has a population doubling time of approximately 38 hours. The NCI-H358 cell line has applications for research relevant to treatments addressing lung cancer.
High Density NCI-H358 cells
Atcc.org
Altogen Biosystems  848 Rainbow Blvd #823  Las Vegas  NV   USA
Telephone   Fax   

3. NCI-H358 Transfection Protocol
Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products
Products > NCI-H358 Transfection Reagent (Bronchioalveolar Cells)
NCI-H358 Transfection Protocol
1. Plate 10, ,000 NCI-H358 cells per well in 0.5 ml of complete growth medium 12–24 hours prior to transfection
2. Wash with 1xPBS and add 0.5 ml of fresh growth medium
3. Prepare transfection complexes by mixing 40 µl of serum-free medium, 5.5 µl of transfection reagent, and
• 750 ng DNA (or mRNA), or
• 30 nM - 50 nM of siRNA (or microRNA)
*Referred to a final volume including growth medium
4. Incubate transfection complexes at RT for minutes
5. Optional: Add 2 µl of Complex Condenser. This reagent reduces the size of transfection complex, therefore increasing transfection efficiency; however, it may increase cell toxicity
6. Add prepared transfection complexes to 0.5 ml of complete growth medium with NCI-H358 cells (from step 2)
7. Incubate cells at 37ºC in a humidified CO2 incubator
8. Assay for phenotype or target gene expression hours after transfection
Optional: Transfection efficiency can be increased by addition of Transfection Enhancer reagent. Add 2 µl of Transfection Enhancer reagent hours after transfection
If the viability of NCI-H358 cells being transfected is affected at hours post-transfection, the level of cytotoxicity can be decreased by changing the growth medium and eliminating redundant exposure of cells to transfectant
Altogen Biosystems  848 Rainbow Blvd #823  Las Vegas  NV   USA
Telephone   Fax   

4. General Lipoplex-mediated Transfection Mechanism of Action
Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products
Products > NCI-H358 Transfection Reagent (Bronchioalveolar Cells)
General Lipoplex-mediated Transfection Mechanism of Action
Altogen Biosystems  848 Rainbow Blvd #823  Las Vegas  NV   USA
Telephone   Fax   

5. NCI-H358 Transfection Kit Product Details
Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products
Products > NCI-H358 Transfection Reagent (Bronchioalveolar Cells)
NCI-H358 Transfection Kit Product Details
A nanoparticle-based liposome formulation
Optimized easy-to-use transfection protocol provided for transfection of siRNA, DNA, mRNA, and microRNA
Kit includes Transfection Enhancer reagent and recommended transfection protocol
High transfection efficacy in the presence of serum
Expand your RNAi application with a reagent optimized for delivery of both siRNA and plasmid
Reproducible transfection results
Works well for standard reverse transfection and high-throughput applications
Developed and manufactured by Altogen Biosystems (
Altogen Biosystems  848 Rainbow Blvd #823  Las Vegas  NV   USA
Telephone   Fax   

6. Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products
Products > NCI-H358 Transfection Reagent (Bronchioalveolar Cells)
Data
Figure 1. Cyclophilin B silencing efficiency was determined by qRT-PCR in the NCI-H358 cells transfected by Cyclophilin B siRNA or non-silencing siRNA control following the recommended transfection protocol. Cyclophilin mRNA expression levels were measured 48 hours post-transfection. 18S rRNA levels were used to normalize the Cyclophilin B data. Values are normalized to untreated sample. Data are presented as means ± SD (n=6).

7. Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products
Products > NCI-H358 Transfection Reagent (Bronchioalveolar Cells)
Data
Figure 2. Protein expression of Cyclophilin B in NCI-H358 cells. DNA plasmid expressing Cyclophilin B or siRNA targeting Cyclophilin B were transfected into NCI-H358 cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.

8. NCI-H358 Transfection Kit Benefits
Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products
Products > NCI-H358 Transfection Reagent (Bronchioalveolar Cells)
NCI-H358 Transfection Kit Benefits
Pre-optimized transfection protocol for NCI-H358 cell line
Compatible with DNA, small RNA (siRNA, shRNA, miRNA), mRNA, and small protein complexing
Free of serum and protein of animal origin
Compatible with standard and reverse transfection methods (both protocols provided in the kit manual)
Easy to use NCI-H358 transfection protocol ensures great performance with expedited experimental timeline
Equally efficient for single or multiple transfections
Can be used for transient transfection and development of stable NCI-H358 cell lines
Bio-degradable after endocytosis
Used for preclinical research worldwide
Altogen Biosystems  848 Rainbow Blvd #823  Las Vegas  NV   USA
Telephone   Fax   